- Home
- TYRA vs SXC Comparison
TYRA vs SXC Comparison
Compare TYRA & SXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- SXC
- Stock Information
- Founded
- TYRA 2018
- SXC 1960
- Country
- TYRA United States
- SXC United States
- Employees
- TYRA N/A
- SXC N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- SXC Steel/Iron Ore
- Sector
- TYRA Health Care
- SXC Industrials
- Exchange
- TYRA Nasdaq
- SXC Nasdaq
- Market Cap
- TYRA 812.7M
- SXC 722.8M
- IPO Year
- TYRA 2021
- SXC N/A
- Fundamental
- Price
- TYRA $14.00
- SXC $10.94
- Analyst Decision
- TYRA Strong Buy
- SXC Strong Buy
- Analyst Count
- TYRA 5
- SXC 1
- Target Price
- TYRA $31.00
- SXC $13.00
- AVG Volume (30 Days)
- TYRA 219.5K
- SXC 1.1M
- Earning Date
- TYRA 11-07-2024
- SXC 01-30-2025
- Dividend Yield
- TYRA N/A
- SXC 4.39%
- EPS Growth
- TYRA N/A
- SXC 55.48
- EPS
- TYRA N/A
- SXC 1.01
- Revenue
- TYRA N/A
- SXC $1,970,000,000.00
- Revenue This Year
- TYRA N/A
- SXC N/A
- Revenue Next Year
- TYRA N/A
- SXC N/A
- P/E Ratio
- TYRA N/A
- SXC $10.81
- Revenue Growth
- TYRA N/A
- SXC N/A
- 52 Week Low
- TYRA $11.24
- SXC $7.47
- 52 Week High
- TYRA $29.60
- SXC $12.82
- Technical
- Relative Strength Index (RSI)
- TYRA 32.68
- SXC 31.29
- Support Level
- TYRA $14.65
- SXC $10.78
- Resistance Level
- TYRA $15.55
- SXC $11.81
- Average True Range (ATR)
- TYRA 0.72
- SXC 0.33
- MACD
- TYRA 0.02
- SXC -0.25
- Stochastic Oscillator
- TYRA 3.12
- SXC 8.29
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About SXC SunCoke Energy Inc.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers.